The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
The present invention relates to a novel antibacterial peptide and a composition comprising the same as an active ingredient. The novel antibacterial peptide of the present invention exhibits excellent antibacterial activity against antibiotic-resistant bacteria as well as Gram-positive bacteria and Gram-negative bacteria and is low in cytotoxicity and, as such, can be advantageously utilized as an active ingredient in an antibiotic, a cosmetic composition, a food additive, a feed additive, a biotic pesticide, a quasi-drug product, and the like.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61Q 17/00 - Préparations protectricesPréparations employées en contact direct avec la peau pour protéger des influences extérieures, p. ex. des rayons du soleil, des rayons X ou d'autres rayons nuisibles, des matériaux corrosifs, des bactéries ou des piqûres d'insectes
The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. In addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p. ex. Lys, Arg
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
According to the manufacturing method of the present invention, Ganirelix can be obtained in high purity and high yield, and the commercial mass-production process therefor is feasible, and also, an economical advantage, that is, the reduction in the production costs compared to conventional technologies, is provided. Furthermore, it is possible to obtain a large quantity of Ganirelix more safely than conventional technologies.
According to the production method of the present invention, AGM peptides that bind specifically to nucleolin can be obtained with high purity and high yields. Accordingly, a method that enables the mass-synthesis of AGM peptides that can be usefully used for diagnosis and targeted drug delivery in cancer therapy, can be presented.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A compound according to the present invention or a pharmaceutically acceptable salt thereof selectively and specifically acts as an agonist for GPR39, promotes the proliferation of intestinal tissue cells and enterohepatic association, promotes cell differentiation, and alleviates inflammation in inflamed intestinal tissue. Thus, the compound can be used in a composition for alleviating and mitigating, preventing, or treating inflammatory bowel disease.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
7.
COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND
A compound according to the present invention or a pharmaceutically acceptable salt thereof selectively and specifically acts as an agonist for GPR39, promotes the proliferation of intestinal tissue cells and enterohepatic association, promotes cell differentiation, and alleviates inflammation in inflamed intestinal tissue. Thus, the compound can be used in a composition for alleviating and mitigating, preventing, or treating inflammatory bowel disease.
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61K 38/00 - Préparations médicinales contenant des peptides
in vitroin vivoin vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
The present invention relates to a novel peptide that specifically binds to nucleolin and, more specifically, to a peptide represented by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition for diagnosing cancer comprising the peptide, and a composition for preventing or treating cancer comprising the peptide or the conjugate. In the present invention, it has been confirmed that a peptide ligand AGM peptide and mutants thereof, as screened using an MAP synthesis method and an OBOC combination method, specifically bind to cancer cells, and a conjugate thereof with an anticancer drug inhibits cancer growth (in vitro and in vivo). Thus, the NCL-targeting AGM peptide can be effectively used for diagnosis and targeted drug delivery in cancer therapy.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention relates to a novel peptide that specifically binds to nucleolin and, more specifically, to a peptide represented by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition for diagnosing cancer comprising the peptide, and a composition for preventing or treating cancer comprising the peptide or the conjugate. In the present invention, it has been confirmed that a peptide ligand AGM peptide and mutants thereof, as screened using an MAP synthesis method and an OBOC combination method, specifically bind to cancer cells, and a conjugate thereof with an anticancer drug inhibits cancer growth (in vitro and in vivo). Thus, the NCL-targeting AGM peptide can be effectively used for diagnosis and targeted drug delivery in cancer therapy.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention relates to a novel antibacterial peptide and a composition comprising same as an active ingredient. The novel antibacterial peptide of the present invention exhibits excellent antibacterial activity against antibiotic-resistant bacteria as well as Gram-positive bacteria and Gram-negative bacteria and is low in cytotoxicity and, as such, can be advantageously utilized as an active ingredient in an antibiotic, a cosmetic composition, a food additive, a feed additive, a biotic pesticide, and a quasi-drug product.
The present invention relates to a novel compound represented by Formula Iand a composition for an anti-diabetes and anti-obesity comprising the same as an active ingredient. The compound or pharmaceutically acceptable salt thereof according to the present invention selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an anti-diabetic effect, and therefore can be utilized as a composition for improving, preventing, or treating diabetes mellitus. hi addition, the compound or pharmaceutically acceptable salt thereof according to the present invention acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.
The present invention relates to a novel compound and a composition for an anti-diabetes and anti-obesity comprising same as an active ingredient. The compound according to the present invention or a pharmaceutically acceptable salt thereof selectively and specifically acts as an agonist of GPR39, activates the mechanism of glucose-dependent insulin secretion in pancreatic beta cells, and significantly increases glucose tolerance and an antidiabetic effect, and therefore can be used as a composition for improving, preventing, or treating diabetes. In addition, the compound according to the present invention or a pharmaceutically acceptable salt thereof acts on GPR39 so as to have lipolytic ability in adipocytes and adipose tissue, and therefore can be utilized as a composition for improving, preventing, or treating obesity.
The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
The present invention pertains to an exenatide analogue glycosylated to a specific residue, and a use thereof. The present invention provides a novel substance for treating diabetes, the novel substance exhibiting improved in vivo stability compared to conventional exenatides and analogues thereof. The present invention pertains to an exenatide dimer analogue and a use thereof. The present invention provides a novel substance for treating diabetes and obesity, the novel substance exhibiting significantly improved in vivo stability compared to conventional exenatides and analogues thereof.
The present invention relates to a cosmetic composition for removing or adsorbing particulate matter containing a fatty acid-amino acid complex or a fatty acid-oligopeptide complex as an active ingredient. The complex of the present invention has an excellent effect of removing particulate matter without being toxic for the skin, and thus can be effectively used as a composition for preventing or treating various diseases caused by particulate matter.
The present invention relates to an active substance-hexapeptide complex and a cosmetic composition containing the same. The active substance-hexapeptide complex of the present invention exhibit, through the binding of organic acids or steroids with hexapeptides, antioxidant and skin regeneration effects superior to those of conventional organic acids, steroids or hexapeptides. Therefore, the active substance-hexapeptide complex and the cosmetic composition comprising the same, of the present invention, are effectively usable for anti-oxidation and skin aging prevention.
A breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as active ingredient has been disclosed. Further, a breast cancer therapeutic agent containing 5′-hydroxy-5-nitro-indirubin-3′-oxime as cyclin-dependent kinase (CDK) inhibitor, wherein said breast cancer is triple negative breast cancer (TNBC) and/or an estrogen receptor (ER) positive breast cancer including the tamoxifen-resistant estrogen receptor (ER) positive breast cancer has been disclosed.
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 209/38 - Atomes d'oxygène en positions 2 et 3, p. ex. isatine
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 38/00 - Préparations médicinales contenant des peptides
23.
TRIPHENYLMETHANE DERIVATIVES WITH SELECTIVE SOLUBILITY, AND USE THEREOF
The present invention relates to triphenylmethane derivatives represented by chemical formula (I), and a use thereof. The present invention has an effect of allowing easy separation and purification of prepared compounds or peptides, thereby having an advantage of enabling commercial mass production. In addition, the present invention uses inexpensive tags which can be recovered and reused, and thus exhibits a very economic effect in terms of production cost.
C07C 47/52 - Composés comportant des groupes —CHO liés à des atomes de carbone de cycles aromatiques à six chaînons
C07C 47/42 - Composés non saturés comportant des groupes —CHO liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un cycle à six chaînons
The present invention provides a novel method for preparing desmopressin by synthesizing a peptide through a solid-phase synthesis method and a solution-phase synthesis method, and then performing a disulfide bond formation reaction in an organic solvent. In the present invention, the solid-phase synthesis reaction and the solution-phase reaction are performed and then the disulfide bond formation reaction of the peptide is performed in the organic solvent, and thus it is easy to separate and purify an object after the reaction is ended, thereby allowing commercial mass production. In addition, the present invention has an economical effect in view of production costs since desmopressin of the present invention has improved yield and purity over desmopressin synthesized by the method used in the art.
The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.
The present invention relates to a curcumin-peptide complex having improved solubility in water compared with curcumin; to a method for improving solubility of curcumin in water; to a method for preparing the complex; and to a cosmetic composition and a functional health food which contain the complex. The present invention provides a curcumin-peptide complex in which a peptide material validated to have biocompatibility and safety is linked to curcumin as a natural resource having a very excellent functional effect via a linker compound, and the curcumin-peptide complex is completely dissolved in water. The present invention provides a method for improving solubility of curcumin in water, thereby contributing to an increase in availability of curcumin as medicines, cosmetics, and food.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
28.
COMPOSITION FOR REGULATING CIRCADIAN RHYTHMS, COMPOSITION FOR DIAGNOSING CIRCADIAN RHYTHM DISORDERS AND DIAGNOSTIC KIT
The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.
The present invention relates to an indirubin-3'-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3'-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.
GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (République de Corée)
ANYGENE CO., LTD. (République de Corée)
Inventeur(s)
Kim, Jae Il
Park, Jin-Suk
Kim, Hyun Jin
Abrégé
The present invention relates to a cellular transmembrane domain and an intracellular transduction system. The cellular transmembrane domain has an excellent effect on genetic immunity problems or cytotoxicity comparing to peptides derived from an existing virus or sequence-specific peptides. Thus, the cellular transmembrane domain can be clinically applied to the human body without concern for side effects and be used in diagnosis and development of novel drugs for various diseases.
The present invention relates to the novel pyrazolodiazepine compounds which potently inhibit the activity of transglutaminase in a dose dependent manner. Accordingly, it has been confirmed that the inventive compounds show potent inhibiting effect on the hyper- activated transglutaminase when the transglutaminase is over-expressed. Therefore the compounds can be useful in treating or preventing the disease caused by increased activation of transglutaminase.
The present invention relates to a multi-functional complex for imaging and drug delivery comprising a plurality of nanoparticles, wherein the nanoparticles comprise: (a) a signal generating core; and a water soluble polymeric outer shell coated on the signal generating core, comprising a surface-anchoring site containing silyl-, hydroxysilyl- or alkoxysilyl-functionalized groups and a drug-binding site.
The present invention relates to a spinorphin derivative useful as a potent and selective human P2X3 receptor antagonist. More particularly, the present invention provides a spinorphin derivative useful as a potent and selective human P2X3 receptor antagonist selected from peptide AVVYPWT, peptide LAVYPWT, peptide LVAYPWT, peptide LVVAPWT and/ or cyclic peptide LWYPWT. Human P2X3 receptor antagonist has been developed on the electrophysiological evaluation of spinorphin peptide derivatives, truncated peptide analogues, cyclic peptides and a retroinverso peptide at human P2X3 receptors to determine the channel blocking activity.
The present invention relates to a method for increasing the binding reversibility of a 쳱-conotoxin to a N-type calcium channel, which comprises preparing a 쳱-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and 3) of the 쳱-conotoxin represented by the formula I, such that the prepared 쳱-conotoxin has the increased binding reversibility to N-type calcium channel. In addition, the present invention relates to a novel 쳱-conotoxin and a pharmaceutical composition having plausible properties in view of blocking activity to and specificity to N-type calcium channel, and dramatically improved binding reversibility to N-type calcium channel.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present invention relates to PAS (Plasmid Acromobacter Secretion) factor mutants, particularly to a PAS factor mutant, vectors carrying the same, and processes for preparing recombinant peptides and proteins using the vectors. The vectors containing the PAS factor mutant enable to express peptides or proteins fused to the PAS factor mutant in much higher level. In addition, transmembrane proteins such as ryanodine receptor and human-origiated proteins such as calcipressin that have been known not to be expressed in conventional vector systems, can be successfully expressed by use of the PAS factor mutant.
C07K 14/28 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Vibrionaceae (F)
36.
POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON
The object of the present invention is to provide a potassium channel opener having benzofuroindole skeleton representing the following formula (I) wherein, R1 is hydrogen, R2 is CF3, R3 is COOH, R4 is hydrogen, R5 is hydrogen or chloride and R6 is hydrogen or chloride.
brevets
